{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T23:03:31Z","timestamp":1770332611048,"version":"3.49.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathologie Biologie"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.patbio.2015.04.003","type":"journal-article","created":{"date-parts":[[2015,5,16]],"date-time":"2015-05-16T03:02:23Z","timestamp":1431745343000},"page":"144-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Meningococcal vaccines: Current state and future outlook"],"prefix":"10.1016","volume":"63","author":[{"given":"M.","family":"Leca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bornet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Montana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Curti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Vanelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.patbio.2015.04.003_bib0505","first-page":"22","article-title":"The use and misuse of media headlines: lessons from the MeNZB immunisation campaign","volume":"122","author":"Turner","year":"2009","journal-title":"N Z Med J"},{"key":"10.1016\/j.patbio.2015.04.003_bib0510","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1590\/0004-282X20130144","article-title":"Invasive meningococcal disease","volume":"71","author":"Strelow","year":"2013","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.patbio.2015.04.003_bib0515","doi-asserted-by":"crossref","first-page":"B71","DOI":"10.1016\/j.vaccine.2009.04.070","article-title":"Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis","volume":"27","author":"Stephens","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0520","first-page":"521","article-title":"Meningococcal vaccines: WHO position paper, November 2011","volume":"86","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.patbio.2015.04.003_bib0525","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(12)61187-8","article-title":"Effect of vaccines on bacterial meningitis worldwide","volume":"380","author":"McIntyre","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2015.04.003_bib0530","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.jinf.2013.09.026","article-title":"Advances towards the prevention of meningococcal B disease: a multidimensional story","volume":"68","author":"Roderick","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.patbio.2015.04.003_bib0535","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patbio.2015.04.003_bib0540","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2015.04.003_bib0545","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1073\/pnas.94.1.271","article-title":"Capsule switching of Neisseria meningitidis","volume":"94","author":"Swartley","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.patbio.2015.04.003_bib0550","doi-asserted-by":"crossref","first-page":"828","DOI":"10.4161\/hv.7.8.16270","article-title":"Meningococcal disease: the advances and challenges of meningococcal disease prevention","volume":"7","author":"Yogev","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.patbio.2015.04.003_bib0555","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1471-2334-10-175","article-title":"The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology","volume":"10","author":"Racloz","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.patbio.2015.04.003_bib0560","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4161\/hv.26816","article-title":"Routine vaccination against MenB: considerations for implementation","volume":"10","author":"Kaaijk","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.patbio.2015.04.003_bib0565","doi-asserted-by":"crossref","first-page":"B10","DOI":"10.1016\/j.vaccine.2011.12.060","article-title":"History of meningococcal vaccines and their serological correlates of protection","volume":"30","author":"Vipond","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0570","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0575","doi-asserted-by":"crossref","first-page":"B40","DOI":"10.1016\/j.vaccine.2011.12.073","article-title":"Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience","volume":"30","author":"Djingarey","year":"2012","journal-title":"Vaccine"},{"issue":"RR-2","key":"10.1016\/j.patbio.2015.04.003_bib0580","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.patbio.2015.04.003_bib0585","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.patbio.2015.04.003_bib0590","unstructured":"INVS. Les infections invasives \u00e0 m\u00e9ningocoque en France en 2011. Available from: URL: http:\/\/www.invs.sante.fr\/Dossiers-thematiques\/Maladies-infectieuses\/Maladies-a-prevention-vaccinale\/Infections-invasives-a-meningocoques\/Donnees-epidemiologiques\/Les-infections-invasives-a-meningocoque-en-France-en-2011. [French], 2014."},{"key":"10.1016\/j.patbio.2015.04.003_bib0595","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3201\/eid1206.051297","article-title":"Social behavior and meningococcal carriage in British teenagers","volume":"12","author":"MacLennan","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.patbio.2015.04.003_bib0600","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0605","doi-asserted-by":"crossref","first-page":"B52","DOI":"10.1016\/j.vaccine.2011.12.068","article-title":"Can we, should we, eradicate the meningococcus?","volume":"30","author":"Maiden","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0610","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","article-title":"From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak","volume":"11","author":"Caron","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.patbio.2015.04.003_bib0615","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection - serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0620","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0625","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2015.04.003_bib0630","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1086\/315833","article-title":"Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992\u20131998","volume":"182","author":"Sacchi","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.patbio.2015.04.003_bib0635","doi-asserted-by":"crossref","first-page":"B42","DOI":"10.1016\/j.vaccine.2009.05.001","article-title":"Meningococcal protein antigens and vaccines","volume":"27","author":"Feavers","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0640","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil","volume":"340","author":"de Moraes","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2015.04.003_bib0645","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease","volume":"13","author":"Boslego","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0650","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH"},{"key":"10.1016\/j.patbio.2015.04.003_bib0655","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2015.04.003_bib0660","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0665","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1016\/j.vaccine.2007.01.023","article-title":"Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand","volume":"25","author":"Oster","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0670","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1016\/j.vaccine.2012.05.051","article-title":"Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac","volume":"30","author":"Caron","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0675","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.vaccine.2005.01.058","article-title":"The concept of \u201ctailor-made\u201d, protein-based, outer membrane vesicle vaccines against meningococcal disease","volume":"23","author":"Holst","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0680","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.patbio.2015.04.003_bib0685","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40259-013-0034-5","article-title":"Genome-based bacterial vaccines: current state and future outlook","volume":"27","author":"Schubert-Unkmeir","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.patbio.2015.04.003_bib0690","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.micpath.2013.02.003","article-title":"Neisseria meningitidis serogroup B vaccine development","volume":"57","author":"Caesar","year":"2013","journal-title":"Microb Pathog"},{"key":"10.1016\/j.patbio.2015.04.003_bib0695","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0165-5728(90)90146-E","article-title":"Evidence for autoimmune antibodies directed against embryonic neural cell adhesion molecules (N-CAM) in patients with group B meningitis","volume":"29","author":"Nedelec","year":"1990","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.patbio.2015.04.003_bib0700","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ijpharm.2014.05.061","article-title":"Evaluation of synergistic effect of biodegradable polymeric nanoparticles and aluminum based adjuvant for improving vaccine efficacy","volume":"471","author":"Bansal","year":"2014","journal-title":"Int J Pharm"},{"key":"10.1016\/j.patbio.2015.04.003_bib0705","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.vaccine.2003.10.005","article-title":"Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers","volume":"22","author":"Bruge","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0710","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jbiotec.2004.03.024","article-title":"Biotechnology and vaccines: application of functional genomics to Neisseria meningitidis and other bacterial pathogens","volume":"113","author":"Serruto","year":"2004","journal-title":"J Biotechnol"},{"issue":"Suppl. 2","key":"10.1016\/j.patbio.2015.04.003_bib0715","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.vaccine.2005.01.103","article-title":"Reverse vaccinology - in search of a genome-derived meningococcal vaccine","volume":"24","author":"Danzig","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0720","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/S0264-410X(00)00554-5","article-title":"Reverse vaccinology, a genome-based approach to vaccine development","volume":"19","author":"Rappuoli","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0725","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0730","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/0-387-25342-4_15","article-title":"Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis","volume":"568","author":"Kelly","year":"2005","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.patbio.2015.04.003_bib0735","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.patbio.2015.04.003_bib0740","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2015.04.003_bib0745","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.patbio.2015.04.003_bib0750","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CVI.00027-10","article-title":"Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine","volume":"17","author":"Lucidarme","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.patbio.2015.04.003_bib0755","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1084\/jem.20020407","article-title":"NadA, a novel vaccine candidate of Neisseria meningitidis","volume":"195","author":"Comanducci","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.patbio.2015.04.003_bib0760","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1086\/424464","article-title":"Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease","volume":"190","author":"Litt","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.patbio.2015.04.003_bib0765","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2958.2004.04423.x","article-title":"Neisseria meningitidis NadA is a new invasion, which promotes bacterial adhesion to and penetration into human epithelial cells","volume":"55","author":"Capecchi","year":"2005","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.patbio.2015.04.003_bib0770","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1073\/pnas.0915162107","article-title":"Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans","volume":"107","author":"Serruto","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.patbio.2015.04.003_bib0775","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4161\/hv.7.6.15482","article-title":"The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans","volume":"7","author":"Toneatto","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.patbio.2015.04.003_bib0780","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1016\/j.vaccine.2010.05.014","article-title":"Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus","volume":"28","author":"Giuliani","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0785","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.patbio.2015.04.003_bib0790","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(98)02326-5","article-title":"Macrophagic myofasciitis: an emerging entity","volume":"352","author":"Gherardi","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2015.04.003_bib0795","unstructured":"Center for Disease Control and prevention. Meningococcal disease. Available from: URL: http:\/\/www.cdc.gov\/meningococcal\/outbreaks\/vaccine-serogroupb.html, 2015."},{"key":"10.1016\/j.patbio.2015.04.003_bib0800","unstructured":"FDA. Trumemba highlights of prescribing informations. Available from: URL: http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM421139.pdf, 2014."},{"key":"10.1016\/j.patbio.2015.04.003_bib0805","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4161\/hv.4.2.4871","article-title":"vaccine development and evaluation of efficacy","volume":"4","author":"Van Alphen","year":"2008","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.patbio.2015.04.003_bib0810","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.patbio.2015.04.003_bib0815","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization - international meeting report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0820","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0825","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2015.04.003_bib0830","unstructured":"Haut Conseil de la Sant\u00e9 Publique. Vaccination contre les infections invasives \u00e0 m\u00e9ningocoque B, place du vaccin Bexsero\u00ae. Available from: URL: http:\/\/www.hcsp.fr\/explore.cgi\/avisrapportsdomaine?clefr=386. [French], 2013."},{"key":"10.1016\/j.patbio.2015.04.003_bib0835","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0840","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.patbio.2015.04.003_bib0845","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.patbio.2015.04.003_bib0850","doi-asserted-by":"crossref","first-page":"B67","DOI":"10.1016\/j.vaccine.2011.12.126","article-title":"The challenge of post-implementation surveillance for novel meningococcal vaccines","volume":"30","author":"Snape","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0855","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1473-3099(13)70037-9","article-title":"Novel assessment of a novel meningitis B vaccine","volume":"13","author":"Gill","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.patbio.2015.04.003_bib0860","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/INF.0b013e31829cfff2","article-title":"Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial","volume":"32","author":"Snape","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.patbio.2015.04.003_bib0865","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.vaccine.2013.03.063","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)","volume":"32","author":"Bettinger","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0870","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/pch\/16.8.e61","article-title":"From genes to vaccine: a breakthrough in the prevention of meningococcal group B disease","volume":"16","author":"Major","year":"2011","journal-title":"Paediatr Child Health"},{"key":"10.1016\/j.patbio.2015.04.003_bib0875","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.patbio.2015.04.003_bib0880","unstructured":"Haut Conseil de la Sant\u00e9 Publique. Avis relatif \u00e0 l\u2019introduction du vaccin Bexsero\u00ae dans la campagne de vaccination contre le m\u00e9ningocoque B:14:P1.7,16 dans les d\u00e9partements de Seine-Maritime et de la Somme. Available from: URL: http:\/\/www.hcsp.fr\/explore.cgi\/avisrapportsdomaine?clefr=373. [French], 2013."},{"key":"10.1016\/j.patbio.2015.04.003_bib0885","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.vaccine.2013.11.042","article-title":"Parental and community acceptance of the benefits and risks associated with meningococcal B vaccines","volume":"32","author":"Marshall","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0890","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(09)61208-3","article-title":"Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials","volume":"374","author":"Prymula","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2015.04.003_bib0895","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/ebn.13.3.76","article-title":"Prophylactic paracetamol at the time of infant vaccination reduces the risk of fever, but also reduces antibody response","volume":"13","author":"Yal\u00e7in","year":"2010","journal-title":"Evid Based Nurs"},{"key":"10.1016\/j.patbio.2015.04.003_bib0900","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40259-013-0029-2","article-title":"Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero\u00ae): a review of its use in primary and booster vaccination","volume":"27","author":"Carter","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.patbio.2015.04.003_bib0905","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1016\/j.vaccine.2014.05.063","article-title":"Aluminium in allergen-specific subcutaneous immunotherapy - a German perspective","volume":"32","author":"Kramer","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0910","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.2174\/092986711795933740","article-title":"Aluminum vaccine adjuvants: are they safe?","volume":"18","author":"Tomljenovic","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.patbio.2015.04.003_bib0915","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(13)62323-5","article-title":"Immunisation against meningococcus B: the case of Spain","volume":"382","author":"Martinon-Torres","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2015.04.003_bib0920","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1473-3099(13)70345-1","article-title":"UK poised to make decision on 4CMenB vaccine","volume":"14","author":"Holmes","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.patbio.2015.04.003_bib0925","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.vaccine.2013.12.066","article-title":"Vaccines at what price?","volume":"32","author":"Stephens","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0930","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(13)61572-X","article-title":"The price of prevention: what now for immunisation against meningococcus B","volume":"382","author":"Moxon","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2015.04.003_bib0935","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0940","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.vaccine.2014.02.054","article-title":"Community, parental and adolescent awareness and knowledge of meningococcal disease","volume":"32","author":"Wang","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0945","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1086\/500512","article-title":"Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine","volume":"193","author":"Vu","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.patbio.2015.04.003_bib0950","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose","volume":"185","author":"Snape","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.patbio.2015.04.003_bib0955","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(99)00252-4","article-title":"Meningococcal conjugate vaccines: new opportunities and new challenges","volume":"354","author":"Maiden","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2015.04.003_bib0960","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","article-title":"Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination","volume":"359","author":"Maiden","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2015.04.003_bib0965","doi-asserted-by":"crossref","first-page":"7752","DOI":"10.1016\/j.vaccine.2011.07.124","article-title":"An experimental outer membrane vesicle vaccine from N.\u00a0meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups","volume":"29","author":"Pinto","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.patbio.2015.04.003_bib0970","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1097-2765(00)80471-2","article-title":"Hypermutation in pathogenic bacteria: frequent phase variation in meningococci is a phenotypic trait of aspecialized mutator biotype","volume":"3","author":"Bucci","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.patbio.2015.04.003_bib0975","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1086\/517439","article-title":"Serogroup B, electrophoretic type 15 Neisseria meningitidis in Canada","volume":"177","author":"Kertesz","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.patbio.2015.04.003_bib0980","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/0970-0218.96085","article-title":"Protein conjugate polysaccharide vaccines: challenges in development and global implementation","volume":"37","author":"Nair","year":"2012","journal-title":"Indian J Community Med"},{"key":"10.1016\/j.patbio.2015.04.003_bib0985","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1128\/JCM.41.12.5783-5786.2003","article-title":"First report of capsule replacement among electrophoretic type 37 Neisseria meningitidis strains in Italy","volume":"41","author":"Stefanelli","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.patbio.2015.04.003_bib0990","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1128\/IAI.00181-09","article-title":"Evidence for capsule switching between carried and disease-causing Neisseria meningitidis strains","volume":"77","author":"Beddek","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.patbio.2015.04.003_bib0995","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tim.2006.01.007","article-title":"Mucosal immunity and optimizing protection with meningococcal serogroup B vaccines","volume":"14","author":"Heyderman","year":"2006","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.patbio.2015.04.003_bib1000","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","article-title":"A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults","volume":"31","author":"Marshall","year":"2013","journal-title":"Vaccine"}],"container-title":["Pathologie Biologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811415000462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811415000462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,25]],"date-time":"2019-08-25T05:32:15Z","timestamp":1566711135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0369811415000462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0369811415000462"],"URL":"https:\/\/doi.org\/10.1016\/j.patbio.2015.04.003","relation":{},"ISSN":["0369-8114"],"issn-type":[{"value":"0369-8114","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meningococcal vaccines: Current state and future outlook","name":"articletitle","label":"Article Title"},{"value":"Pathologie Biologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.patbio.2015.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}